MTOR and hepatocellular carcinoma: On the other hand, exploring EIF3B inhibitors with existing MAPK pathway blockers (e.g., trametinib) could synergistically enhance efficacy, building on preclinical data from HCC where EIF3B knockdown synergized with mTOR inhibitors.